Venous Thromboembolism Market Anticipated To Witness Robust Growth, Surpassing $3.02 Billion By 2029

The Venous Thromboembolism Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Venous Thromboembolism Market Size and Its Estimated Growth Rate?
The market for venous thromboembolism has seen continuous expansion in the past years. It is projected to increase from $2.44 billion in 2024 to $2.55 billion in 2025, indicating a compound annual growth rate (CAGR) of 4.4%. This past growth is primarily due to factors such as growing elderly population, development in anticoagulants, reimbursement tactics, and heightened investments.

In the coming years, the market size for venous thromboembolism is projected to grow steadily. By 2029, it is anticipated to reach $3.02 billion, boasting a compound annual growth rate (CAGR) of 4.4%. The growth during the forecast period is likely due to factors such as improved access to global healthcare, genetic risk evaluation, telemedicine, remote surveillance, as well as patient education and support. Looking toward the future, one can expect trends like extended thromboprophylaxis, innovative oral anticoagulants, customized treatment approaches, and sophisticated diagnostic imaging techniques.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13001

How Are Emerging Segments Shaping the Venous Thromboembolism Market Landscape?
The venous thromboembolism market covered in this report is segmented -

1) By Type: Deep Vein Thrombosis, Pulmonary Embolism, Other Types
2) By Treatment: Anti-Clotting Medications, Mechanical Devices, Thrombolytic Therapy, Other Treatment
3) By End Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:
1) By Deep Vein Thrombosis (DVT): Proximal DVT, Distal DVT, Asymptomatic DVT
2) By Pulmonary Embolism (PE): Acute PE, Chronic PE, Submassive PE
3) By Other Types: Thrombophlebitis, Superficial Vein Thrombosis, Post-Thrombotic Syndrome

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13001&type=smp

Which Growth Factors Are Influencing Venous Thromboembolism Market Expansion?
The strengthening and growth of the healthcare infrastructure are predicted to fuel the venous thromboembolism market growth in the future. The healthcare industry encompasses the consolidation of various sectors of an economic system, all working towards products and services that aim to heal, prevent, rehabilitate and offer palliative care for patients. The growth of this industry aids in developing crucial infrastructures, practices, policies, and educational programs needed for the implementation of VTE prevention protocols. As an illustration, in May 2023, the American Health Care Association, a nonprofit organization in the US, revealed a growth in the number of US hospitals from 6,093 in 2022 to 6,129. Another significant highlight in May 2023 was from the Office for National Statistics, a statistics authority in the UK which reported a healthcare expenditure of approximately £292 billion in 2023, indicating a 5.6% nominal increase. Further, there was a 2.8% real-term rise in the long-term health and social care expenditure in 2022. Thus, the growth of the healthcare industry is significantly contributing to the expansion of the venous thromboembolism market. The anticipated rise in orthopedic procedures will further enhance the venous thromboembolism market in the future. Orthopedic procedures are surgeries aimed at rectifying conditions of the spine and joints as well as skeletal deformations. Several of such procedures, including total knee arthroplasty (TKA), total hip arthroplasty (THA), and hip fracture surgery (HFS), have a high VTE risk. This has resulted in the increased use of compression devices for DVT prophylaxis, aimed at preventing the formation of blood clots in the deep veins of legs that can induce venous thromboembolism (VTE). Substantiating this, a study published by the National Library of Medicine, a US-based biomedical library, in February 2023, predicts a substantial increase in THA and TKA procedures to 719,364 and 1,222,988 respectively by 2040. Furthermore, it is anticipated that by 2060, TKAs will reach 2,917,959, while THAs will total 1,982,099. Therefore, the projected growth in orthopedic procedures is set to drive the venous thromboembolism market further.

Who Are the Dominant Players Across Different Venous Thromboembolism Market Segments?
Major companies operating in the venous thromboembolism market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S, Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Glenmark Pharmaceuticals Ltd., Portola Pharmaceuticals Inc.

What Are the Latest Developing Trends in the Venous Thromboembolism Market?
Leading firms in the venous thromboembolism market are innovating and introducing novel anticoagulant medications in an effort to maintain market dominance. These advancements in anticoagulants can potentially produce more effective treatments for preventing or curing venous thromboembolism. For example, Anthos Therapeutics, an American company specializing in clinical-stage biotherapeutics, gained official approval in September 2022 from the US Food and Drug Administration (FDA) for their new anticoagulant medicine, abelacimab. This new, fully human monoclonal antibody drug is designed to prevent stroke and systemic embolism in patients with atrial fibrillation. The innovative, once-monthly, dual-action antibody, abelacimab, is engineered to promote hemostasis-sparing anticoagulation by blocking Factor XI.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report

Which Geographic Regions Are Expected to Dominate the Venous Thromboembolism Market in the Coming Years?
North America was the largest region in the venous thromboembolism market in 2024. The regions covered in venous thromboembolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Venous Thromboembolism Market?
2. What is the CAGR expected in the Venous Thromboembolism Market?
3. What Are the Key Innovations Transforming the Venous Thromboembolism Industry?
4. Which Region Is Leading the Venous Thromboembolism Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.